Vein Center at Austin Heart Medical Team

Born and raised in the Chicago area, Dr. Jay Pandya earned his medical degree from Rush Medical College, and went on to complete a cardiology fellowship at Northwestern University in Chicago. He then completed a second fellowship in interventional cardiology at the University of Illinois, where he was trained in advanced coronary and peripheral vascular/arterial interventions. At that time he was mentored in advanced radial artery catheterization techniques, and now performs the vast majority of his heart procedures through the wrist, as well as many of his peripheral vascular procedures.

In addition to being a specialist in minimally invasive peripheral arterial interventions, Dr Pandya also provides complex percutaneous therapy for advanced venous conditions, including treatment for DVTs (blood clots in the arms/legs), pulmonary embolisms (blood clots in the lung), venous ulcers, and varicose veins.

Dr. Pandya believes a major role for physicians is to educate patients on their condition, as well as on potential treatment options. In his spare time, he enjoys being with his family, traveling, hiking, music, and mountain biking.

Office Locations

Harker Heights, Round Rock, Temple

Media Features

• Seton uses low-risk procedure to diminish blood clots - March 15, 2015 (The Killeen Daily Herald, Killeen, TX)

Publications

• PANDYA SB, Kim YH, Meyers SN, Davidson CJ, Flaherty JD, Park DW, Mediratta A, Pieper K, Reyes E, Bonow RO, Park SJ, Beohar N. Drug-Eluting Stents versus Bare Metal Stents in Unprotected Left Main Coronary Artery Stenosis: a Meta-Analysis, Journal of the American College of Cardiology: Cardiovascular Interventions, June 2010; Vol 3 No 6: 602-611
• Beohar N, Rapp J, PANDYA SB, Losordo DW. Rebuilding the Damaged Heart: The Role of Cytokines and Growth Factors in the Treatment of Ischemic Heart Disease, Journal of the American College of Cardiology, October 2010; Vol 56, No 16: 1287-1297
• Rajamannan NM, Nealis TB, Subramanian M, PANDYA SB, Stock S, Ignatiev CI, Sebo TJ, Rosengart T, Edwards WD, McCarthy PM, Bonow RO, Spelsberg TC. Calcified Rheumatic Valve Neoangiogenesis Is Associated With Vascular Endothelial Growth Factor Expression and Osteoblast-Like Bone Formation, Circulation 2005; 111: 3296 - 3301
• Rajaram V, PANDYA SB, Patel S, Meyer PM, Goldin M, Feinstein MJ, Neems R, Liebson PR, Fiedler BM, Macioch JE, Feinstein SB. Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy, American Journal of Cardiology 2004; 93(11A): 32C-48C
• Patel SN, Rajaram V, PANDYA SB, Fiedler BM, Bai CJ, Neems R, Feinstein M, Goldin M, Feinstein SB. Emerging, Noninvasive Surrogate Markers of Atherosclerosis, Current Atherosclerosis Reports 2004; 6(1): 60-8

Abstracts

• Rajamannan NM, Gallagher PS, Le TA, PANDYA SB, MConnel J, Singh R, Gocek J, Caira F, Subramaniam M, Spelsberg TC. Atorvastatin Attenuates Vascular Glomeruli Atherosclerosis in Experimental Hypercholesterolemia., Journal of the American College of Cardiology. 2005; 45(3) Supplement 1:A367

Presentations

• PANDYA SB, Subramanian M, Stock S, Spelsberg TC, McCarthy P, Bonow RO, Rajamannan NM. Degenerative Versus Rheumatic Mitral Valve Disease: A Comparison of Cellular Proliferation and Osteoblast Mediated Extracellular Matrix Production, American College of Cardiology Scientific Session Orlando, FL March 2005
• PANDYA SB, Subramanian M, Stock S, Spelsberg TC, McCarthy P, Bonow RO, Rajamannan NM. Human Mitral Valve Degeneration is Associated with an Osteoblast Phenotype, Central Society for Clinical Research / Midwestern Section American Federation for Medical Research Chicago IL March, 2005

Education

Medical School Rush Medical College, Chicago, Illinois

Residency Internal Medicine, McGaw Medical Center of Northwestern University, Northwestern Memorial Hospital/VA Chicago, Chicago, Illinois

Fellowship Cardiovascular Disease, McGaw Medical Center of Northwestern University, Northwestern Memorial Hospital/VA Chicago, Chicago, Illinois
Interventional Cardiology Fellowship: UIC-Christ Advocate Medical Center, Chicago, Illinois

Certifications & Memberships

Interventional Cardiology

Gender

Male

Languages Spoken

English

Specialty

Interventional Cardiology

Sub Specialties

Peripheral Vascular Interventions
Venous Disorders

Dr. Cigarroa earned his Bachelor of Science from the University of Notre Dame in 2009. In 2013, he earned his medical degree from the University of Texas Health Science Center at San Antonio (UTHSCSA). He completed an internal medicine residency at UTHSCSA followed by a one year position as chief resident and junior faculty member in the Department of Medicine. Dr. Cigarroa furthered his medical training by completing a cardiovascular disease fellowship at UTHSCSA in 2020 followed by an interventional cardiology fellowship at Beaumont Hospital in Royal Oak, Michigan in 2021.

Dr. Matthew Selmon is a native Texan who spent 22 years in the San Francisco Bay area as a practicing cardiologist, clinical researcher, and co-founder of Lumend, maker of the Frontrunner and Outback total occlusion devices now sold by J&J Cordis.

Dr. Selmon earned his medical degree at Southwestern Medical School in Dallas, Texas. He went on to complete a cardiology fellowship at University of Missouri in Columbia, Missouri. He then completed a second fellowship in Interventional Cardiology at Sequoia Hospital in Redwood City, California. He is Board Certified in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology.

While practicing cardiology in California, Dr. Selmon partnered with world renowned cardiologist, Dr. John Simpson, on the coronary and peripheral device development company, Lumend, where he also worked as Chief Medical Officer. After Lumend was acquired in 2005 by J&J Cordis, Dr. Selmon returned to Texas to practice cardiology at Austin Heart, specializing in Interventional Cardiology, Peripheral Vascular Intervention, and Venous Disease with a special interest in chronic total occlusions (CTOs). He established Austin Heart’s new Vein Center in 2010 and currently serves as the Medical Director as he continues his work in coronary and peripheral vascular intervention.

Dr. Selmon served as the national Principal Investigator for the CONNECT II Ocelot Trial, a new OCT directed peripheral chronic total occlusion device, and recently presented the findings at the VIVA Late Breaking Clinical Trials session.

Awards and Special Recognition

Best Austin Doctors 2014

Specialty

Interventional Cardiology, Vein Disease

Office Locations

Heart Hospital, La Grange

News Coverage

Avinger Enrolls First European PAD Patient in CONNECT II Global Clinical Trial—Co-principal investigators for the trial include Arne Schwindt, MD of St. Franziskus Hospital in Muenster, Germany, and Matthew Selmon, MD, Austin Heart

Education

Residency University of Missouri-Columbia School of Medicine, Columbia, MO

Fellowship University of Missouri-Columbia School of Medicine, Columbia, MO

Certifications & Memberships

Cardiovascular Disease, Interventional Cardiology

Gender

Male

Languages Spoken

English

Specialty

Interventional Cardiology

Sub Specialties

Peripheral Vascular Interventions

Venous Disorders